Effect of selective LRRK2 kinase inhibition on nonhuman primate lung

Science Translational Medicine

Volumn 7, Issue 273, 2015, Pages 273ra15-

  Fuji, Reina N ^a   Flagella, Michael ^a   Baca, Miriam ^a   Baptista, Marco A S ^b   Brodbeck, Jens ^a   Chan, Bryan K ^a   Fiske, Brian K ^b   Honigberg, Lee ^a   Jubb, Adrian M ^a   Katavolos, Paula ^a   Lee, Donna W ^a   Lewin Koh, Sock Cheng ^a   Lin, Tori ^a   Liu, Xingrong ^a   Liu, Shannon ^a   Lyssikatos, Joseph P ^a   O'Mahony, Jennifer ^a   Reichelt, Mike ^a   Roose Girma, Merone ^a   Sheng, Zejuan ^a   Sherer, Todd ^b   Smith, Ashley ^a   Solon, Margaret ^a   Sweeney, Zachary K ^a   Tarrant, Jacqueline ^a   Urkowitz, Alison ^b   Warming, Søren ^a   Yaylaoglu, Murat ^a   Zhang, Shuo ^a   Zhu, Haitao ^a   Estrada, Anthony A ^a   Watts, Ryan J ^a   more..

^a GENENTECH INC   (United States)

^b THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENZYME INHIBITOR; GLYCEROPHOSPHATE; GNE 0877; GNE 7915; LEUCINE RICH REPEAT KINASE 2; LEUCINE RICH REPEAT KINASE 2 INHIBITOR; MESSENGER RNA; UNCLASSIFIED DRUG; (4-(4-(ETHYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YLAMINO)-2-FLUORO-5-METHOXYPHENYL)(MORPHOLINO)METHANONE; 2-METHYL-2-(3-METHYL-4-((4-(METHYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL)AMINO)-1H-PYRAZOL-1-YL)PROPANENITRILE; LRRK2 PROTEIN, HUMAN; LRRK2 PROTEIN, MOUSE; MORPHOLINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HAPLORHINI; KIDNEY STRUCTURE; KNOCKOUT MOUSE; LAMELLAR BODY; LUNG ALVEOLUS CELL TYPE 2; LUNG STRUCTURE; LUNG TOXICITY; LYSOSOME; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PHENOTYPE; PRIMATE; PROTEIN EXPRESSION; RODENT; TOXICITY TESTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CHEMISTRY; CONGENITAL MALFORMATION; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEK293 CELL LINE; HUMAN; KIDNEY; LUNG; LUNG ALVEOLUS CELL; MACACA FASCICULARIS; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE; URINE;

ANIMALS; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEK293 CELLS; HUMANS; KIDNEY; LUNG; MACACA FASCICULARIS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHOLINES; PNEUMOCYTES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRIMIDINES; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 84922674609     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa3634     Document Type: Article

References (38)

1. A. Zimprich, S. Biskup, P. Leitner, P. Lichtner, M. Farrer, S. Lincoln, J. Kachergus, M. Hulihan, R. J. Uitti, D. B. Calne, A. J. Stoessl, R. F. Pfeiffer, N. Patenge, I. C. Carbajal, P. Vieregge, F. Asmus, B. Müller-Myhsok, D. W. Dickson, T. Meitinger, T. M. Strom, Z. K. Wszolek, T. Gasser, Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron 44, 601-607 (2004).
2. C. Paisán-Ruíz, S. Jain, E. W. Evans, W. P. Gilks, J. Simón, M. van der Brug, A. López de Munain, S. Aparicio, A. M. Gil, N. Khan, J. Johnson, J. R. Martinez, D. Nicholl, I. M. Carrera, A. S. Pena, R. de Silva, A. Lees, J. F. Martí-Massó, J. Pérez-Tur, N. W. Wood, A. B. Singleton, Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600 (2004).
3. V. Bonifati, LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg) - Linking familial and sporadic Parkinson's disease. Neurochem. Res. 32, 1700-1708 (2007).
4. D. G. Healy, M. Falchi, S. S. O'Sullivan, V. Bonifati, A. Durr, S. Bressman, A. Brice, J. Aasly, C. P. Zabetian, S. Goldwurm, J. J. Ferreira, E. Tolosa, D. M. Kay, C. Klein, D. R. Williams, C. Marras, A. E. Lang, Z. K. Wszolek, J. Berciano, A. H. Schapira, T. Lynch, K. P. Bhatia, T. Gasser, A. J. Lees, N. W. Wood; International LRRK2 Consortium, Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: A case-control study. Lancet Neurol. 7, 583-590 (2008).
5. J. Kachergus, I. F. Mata, M. Hulihan, J. P. Taylor, S. Lincoln, J. Aasly, J. M. Gibson, O. A. Ross, T. Lynch, J. Wiley, H. Payami, J. Nutt, D. M. Maraganore, K. Czyzewski, M. Styczynska, Z. K. Wszolek, M. J. Farrer, M. Toft, Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: Evidence of a common founder across European populations. Am. J. Hum. Genet. 76, 672-680 (2005).
6. H. Melrose, Update on the functional biology of Lrrk2. Future Neurol. 3, 669-681 (2008).
7. A. B. West, D. J. Moore, S. Biskup, A. Bugayenko, W. W. Smith, C. A. Ross, V. L. Dawson, T. M. Dawson, Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U.S.A. 102, 16842-16847 (2005).
8. J. C. Dächsel, M. J. Farrer, LRRK2 and Parkinson disease. Arch. Neurol. 67, 542-547 (2010).
9. M. R. Cookson, The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat. Rev. Neurosci. 11, 791-797 (2010).
10. I. Martin, V. L. Dawson, T. M. Dawson, Recent advances in the genetics of Parkinson's disease. Annu. Rev. Genomics Hum. Genet. 12, 301-325 (2011).
11. S. J. Orenstein, S. Kuo, I. Tasset, E. Arias, H. Koga, I. Fernandez-Carasa, E. Cortes, L. S. Honig, W. Dauer, A. Consiglio, A. Raya, D. Sulzer, A. M. Cuervo, Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 16, 394-406 (2013).
12. B. M. Law, V. A. Spain, V. H. Leinster, R. Chia, A. Beilina, H. J. Cho, J. M. Taymans, M. K. Urban, R.M. Sancho, M. Blanca Ramírez, S. Biskup, V. Baekelandt, H. Cai, M. R. Cookson, D. C. Berwick, K. Harvey, A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation. J. Biol. Chem. 289, 895-908 (2014).
13. E. Greggio, S. Jain, A. Kingsbury, R. Bandopadhyay, P. Lewis, A. Kaganovich, M. P. van der Brug, A. Beilina, J. Blackinton, K. J. Thomas, R. Ahmad, D. W. Miller, S. Kesavapany, A. Singleton, A. Lees, R. J. Harvey, K. Harvey, M. R. Cooksona, Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23, 329-341 (2006).
14. C. J. Gloeckner, N. Kinkl, A. Schumacher, R. J. Braun, E.O'Neill, T. Meitinger, W. Kolch, H. Prokisch, M. Ueffing, The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223-232 (2006).
15. 1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci. Transl. Med. 4, 164ra161 (2012).
16. A. A. Estrada, X. Liu, C. Baker-Glenn, A. Beresford, D. J. Burdick, M. Chambers, B. K. Chan, H. Chen, X. Ding, A. G. DiPasquale, S. L. Dominguez, J. Dotson, J. Drummond, M. Flagella, S. Flynn, R. Fuji, A. Gill, J. Gunzner-Toste, S. F. Harris, T. P. Heffron, T. Kleinheinz, D. W. Lee, C. E. Le Pichon, J. P. Lyssikatos, A. D. Medhurst, J. G. Moffat, S. Mukund, K. Nash, K. Scearce-Levie, Z. Sheng, D. G. Shore, T. Tran, N. Trivedi, S. Wang, S. Zhang, X. Zhang, G. Zhao, H. Zhu, Z. K. Sweeney, Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J. Med. Chem. 55, 9416-9433 (2012).
17. A. A. Estrada, B. K. Chan, C. Baker-Glenn, A. Beresford, D. J. Burdick, M. Chambers, H. Chen, S. L. Dominguez, J. Dotson, J. Drummond, M. Flagella, R. Fuji, A. Gill, J. Halladay, S. F. Harris, T. P. Heffron, T. Kleinheinz, D. W. Lee, C. E. Le Pichon, X. Liu, J. P. Lyssikatos, A. D. Medhurst, J. G. Moffat, K. Nash, K. Scearce-Levie, Z. Sheng, D. G. Shore, S. Wong, S. Zhang, X. Zhang, H. Zhu, Z. K. Sweeney, Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J. Med. Chem. 57, 921-936 (2014).
18. M. C. Herzig, C. Kolly, E. Persohn, D. Theil, T. Schweizer, T. Hafner, C. Stemmelen, T. J. Troxler, P. Schmid, S. Danner, C. R. Schnell, M. Mueller, B. Kinzel, A. Grevot, F. Bolognani, M. Stirn, R. R. Kuhn, K. Kaupmann, P. H. van der Putten, G. Rovelli, D. R. Shimshek, LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet. 20, 4209-4223 (2011).
19. P. J. Meikle, S. Duplock, D. Blacklock, P. D. Whitfield, G. Macintosh, J. J. Hopwood, M. Fuller, Effect of lysosomal storage on bis(monoacylglycero)phosphate. Biochem. J. 411, 71-78 (2008).
20. E. A. Tengstrand, G. T. Miwa, F. Y. Hsieh, Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities. Expert Opin. Drug Metab. Toxicol. 6, 555-570 (2010).
21. N. Mesens, M. Desmidt, G. R. Verheyen, S. Starckx, S. Damsch, R. De Vries, M. Verhemeldonck, J. Van Gompel, A. Lampo, L. Lammens, Phospholipidosis in rats treated with amiodarone: Serum biochemistry and whole genome micro-array analysis supporting the lipid traffic jam hypothesis and the subsequent rise of the biomarker BMP. Toxicol. Pathol. 40, 491-503 (2012).
22. K. L. Thompson, J. Zhang, S. Stewart, B. A. Rosenzweig, K. Shea, D. Mans, T. Colatsky, Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats. Toxicol. Lett. 213, 285-291 (2012).
23. N. Liu, E. A. Tengstrand, L. Chourb, F. Y. Hsieh, Di-22:6-bis(monoacylglycerol)phosphate: A clinical biomarker of drug-induced phospholipidosis for drug development and safety assessment. Toxicol. Appl. Pharmacol. 279, 467-476 (2014).
24. K. Umetani, M. Abe, K. Kawabata, T. Iida, I. Kohno, T. Sawanobori, K. Kugiyama, SP-D as a marker of amiodarone-induced pulmonary toxicity. Intern. Med. 41, 709-712 (2002).
25. D. Galter, M. Westerlund, A. Carmine, E. Lindqvist, O. Sydow, L. Olson, LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol. 59, 714-719 (2006).
26. S. Biskup, D. J. Moore, A. Rea, B. Lorenz-Deperieux, C. E. Coombes, V. L. Dawson, T. M. Dawson, A. B. West, Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci. 8, 102 (2007).
27. Y. Tong, H. Yamaguchi, E. Giaime, S. Boyle, R. Kopan, R. J. Kelleher, J. Shen, Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice. Proc. Natl. Acad. Sci. U.S.A. 107, 9879-9884 (2010).
28. D. Ness, Z. Ren, S. Gardai, D. Sharpnack, V. J. Johnson, R. J. Brennan, E. F. Brigham, A. J. Olaharski, Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis. PLOS One 8, e66164 (2013).
29. M. A. Baptista, K. D. Dave, M. A. Frasier, T. B. Sherer, M. Greeley, M. J. Beck, J. S. Varsho, G. A. Parker, C. Moore, M. J. Churchill, C. K. Meshul, B. K. Fiske, Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLOS One 8, e80705 (2013).
30. N. Dzamko, G. Chua, M. Ranola, D. B. Rowe, G. M. Halliday, Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients. J. Parkinsons Dis. 3, 145-152 (2013).
31. P. Miklavc, K. Ehinger, K. E. Thompson, N. Hobi, D. R. Shimshek, M. Frick, Surfactant secretion in LRRK2 knock-out rats: Changes in lamellar body morphology and rate of exocytosis. PLOS One 9, e84926 (2014).
32. H. D. Gallala, K. Sandhoff, Biological function of the cellular lipid BMP-BMP as a key activator for cholesterol sorting and membrane digestion. Neurochem. Res. 36, 1594-1600 (2011).
33. S. A. Papiris, C. Triantafillidou, L. Kolilekas, D. Markoulaki, E. D. Manali, Amiodarone: Review of pulmonary effects and toxicity. Drug Saf. 33, 539-558 (2010).
34. M. Schwaiblmair, T. Berghaus, T. Haeckel, T. Wagner, W. von Scheidt, Amiodarone-induced pulmonary toxicity: An under-recognized and severe adverse effect? Clin. Res. Cardiol. 99, 693-700 (2010).
35. J. A. Shayman, A. Abe, Drug induced phospholipidosis: An acquired lysosomal storage disorder. Biochim. Biophys. Acta 1831, 602-611 (2013).
36. E. J. Parkinson-Lawrence, T. Shandala, M. Prodoehl, R. Plew, G. N. Borlace, D. A. Brooks, Lysosomal storage disease: Revealing lysosomal function and physiology. Physiology 25, 102-115 (2010).
37. S. Warming, R. A. Rachel, N. A. Jenkins, N. G. Copeland, Zfp423 is required for normal cerebellar development. Mol. Cell. Biol. 26, 6913-6922 (2006).
38. J. L. Ziskin, D. Dunlap, M. Yaylaoglu, I. K. Fodor, W. F. Forrest, R. Patel, N. Ge, G. G. Hutchins, J. K. Pine, P. Quirke, H. Koeppen, A. M. Jubb, In situ validation of an intestinal stem cell signature in colorectal cancer. Gut 62, 1012-1023 (2013).